查詢結果分析
來源資料
相關文獻
- Clinical Significance of Changes in Serum Hepatitis B Virus DNA Titer in Patients with Chronic Hepatitis B Treated with Interferon
- 慢性B型肝炎之治療
- Detection and Treatment of Acute Hepatitis C by Needlestick Among Medical Personnel
- 臺灣肝臟病系列(41):慢性B型肝炎HBsAg陰轉後的肝炎
- 干擾素治療引發之神經精神系統併發症
- 慢性B型肝炎的藥物治療
- 慢性B型肝炎之自然病史
- 慢性B型肝炎之藥物治療
- Acquired Immunodeficiency Syndrome and Cytomegalovirus Gastritis in a Patient with Decompensated Liver Cirrhosis and Hepatocellular Carcinoma: Report of a Case
- 慢性B型肝炎中西醫之治療
頁籤選單縮合
題 名 | Clinical Significance of Changes in Serum Hepatitis B Virus DNA Titer in Patients with Chronic Hepatitis B Treated with Interferon=接受干擾素治療的慢性B型肝炎病人其血中B型肝炎病毒核酸濃度變化之臨床意義 |
---|---|
作 者 | 黃信彰; 盧瑞華; 王苑貞; 朱正偉; 吳肇卿; 張扶陽; 李壽東; | 書刊名 | 中華醫學雜誌 |
卷 期 | 63:1 2000.01[民89.01] |
頁 次 | 頁1-7 |
分類號 | 415.415 |
關鍵詞 | 慢性B型肝炎; 血清B型肝炎病毒核酸; 干擾素治療; Chronic hepatitis B; Hepatitis B virus DNA; Interferon-α; |
語 文 | 英文(English) |
中文摘要 | 背景:干擾素是目前國內唯一被核准用來治療慢性B型肝炎之藥物,然而國內相關報導並不多。同時,在干擾素治療中,尚未清楚血清B型肝炎病毒核酸(HBV DNA)濃度之變化及其對療效之影響。 方法:20位血清e抗原及HBV DNA陽性之慢性B型肝炎病人,接受干擾素-α 2a 450萬單位每週3次皮下注射治療,共24週,在治療結束後再追蹤24週。同時,選取20年齡及性別相配之慢性B型肝炎病人作對照組。治療有效之定義為治療結束後24週的血清e抗原轉換(e-seroconversion)及血清轉氨�t(ALT)值恢復正常。血清HBV DNA利用側鏈DNA訊號放大(bDNA)分析法偵測。 結果:兩組病人在治療前之血清轉氨�t值及血清HBV DNA濃度未有顯著差異。在治療結束半年後發現,治療組中有6位病人(30%)有e抗原轉換現象,而對照組有4位(20%),在統計學上未達顯著差異(p>0.05)。血清HBV DNA濃度在接受干擾素治療後均有下降,而只有最後治療有效的病人,其血清HBV DNA濃度持續維持在測不到的水平。6位干擾素治療成功的病人中,有4位的血清HBV DNA在治療第12週已呈陰性;而治療失敗的14位之血清HBV DNA均仍呈陽性(p=0.001)。多變項邏輯回歸分析顯示,干擾素治療第12週時,bDNA分析法偵測不到血清HBV DNA是治療成功的有意義預測因子。 結論:使用450萬單位干擾素-α 2a每週3次皮下注射,共24週,治療慢性B型肝炎,可成功地使30%病人在治療結束後24週有e抗原轉換現象及血清ALT值恢復正常。而在干擾素治療第12週時,利用bDNA分析法無法偵測到血清HBV DNA是預測治療成功之重要因素。 |
英文摘要 | Background: Interferon (IFN) has been used in the treatment of patients with chronic hepatitis B virus (HBV) infection. Nonetheless, the changes in serum HBV DNA titer during IFN treatment and the effect of these changes on the therapeutic results have not been well studied. Methods: Twenty patients with chronic hepatitis B who were positive for serum hepatitis B e antigen (HBeAg) and HBV DNA received IFN-α 2a 4.5 million units by subcutaneous injection three times a week for 24 weeks. Twenty age- and sex-matched patients with chronic hepatitis B were selected as a control group. Treatment response was defined as the normalization of serum alanine aminotransferase (ALT) and the seroconversion of serum HBeAg 24 weeks after discontinuation of the IFN treatment. Serum HBV DNA was measured using the branched DNA (bDNA) signal amplification assay. Results: There was no significant difference in pretreatment mean serum ALT and HBV DNA titer in either the IFN-treated or the control group. Treatment response was found in six (30%) of 20 IFN-treated patients and in four (20%) of 20 control patients (p>0.05). Serum HBV DNA titer fell after IFN treatment and remained undetectable only in patients with final treatment response. Serum HBV DNA was negative at week 12 of the IFN treatment in four (67%) of six patients with treatment responses, significantly higher than in none (0%) of 14 patients without a treatment response (p=0.001). Multivariate logistic regression revealed that the negativity of serum HBV DNA at week 12 of the IFN treatment successfully predicted treatment response. Conclusions: Thirty percent of the patients with chronic hepatitis B responded to IFN-α 2a 4.5 million units subcutaneously injected three times a week for 24 weeks. Negativity of serum HBV DNA measured by bDNA assay at week 12 of the IFN treatment may suggest a beneficial treatment outcome. |
本系統中英文摘要資訊取自各篇刊載內容。